Advice
Following a full submission
Bemiparin (Zibor) is not recommended for use within NHS Scotland for the prevention of thromboembolic events in patients undergoing orthopaedic surgery.
Bemiparin was associated with a lower incidence of thromboembolic complications than unfractionated heparin and was non-inferior to another low molecular weight heparin.
The cost effectiveness has not been convincingly addressed for the Scottish context.
Download detailed advice50KB (PDF)
Medicine details
- Medicine name:
- Bemiparin, 3500 IU in 0.2 ml injection for sub-cutaneous administration (Zibor®)
- SMC ID:
- 204/05
- Indication:
- Prevention of thromboembolic disease in patients undergoing orthopaedic surgery
- Pharmaceutical company
- Amdipharm PLC
- BNF chapter
- Cardiovascular system
- Submission type
- Full
- Status
- Not recommended
- Date advice published
- 10 October 2005